California is currently home to 5585 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Recruiting
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Sutter Auburn Faith Hospital, Auburn, California
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: Neumora Investigator Site, Cerritos, California
Conditions: Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: Neumora Investigator Site, Encino, California
Conditions: Major Depressive Disorder
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Recruiting
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/16/2025
Locations: Cancer and Blood Specialty Clinic, Long Beach, California
Conditions: Melanoma
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: John Muir Physician Network Research Center, Concord, California
Conditions: Type 2 Diabetes, Obesity
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: USC Keck, Los Angeles, California
Conditions: Aortic Aneurysm, Abdominal
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Encinitas, California, Encinitas, California
Conditions: Alopecia Areata
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Recruiting
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Irvine Clinical Research, Irvine, California
Conditions: Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Recruiting
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androg... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/16/2025
Locations: Stanford University, Palo Alto, California
Conditions: Oligometastatic Prostate Cancer (OMPC)
The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy
Recruiting
1. The purpose of the research is to assess the efficacy of postoperative immersive virtual reality (iVR) compared to a standard multimodal pain regimen including opioids and a local block on acute postoperative pain management following hip arthroscopy 2. The primary research procedures are medical record review for demographic information, head-mounted immersive virtual reality experience in PACU, and pre-operative and post-operative surveys 3. The study will enroll adult patients of all ages... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Kerlan Jobe, Los Angeles, California
Conditions: Hip Pain Chronic
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Providence Medical Foundation, Santa Rosa, California
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Newport Huntington Medical Group, Huntington Beach, California
Conditions: Rheumatoid Arthritis